
FDMT Stock Forecast & Price Target
FDMT Analyst Ratings
Bulls say
4D Molecular Therapeutics is a biotechnology company with a diversified gene therapy product pipeline that has shown promise in late-stage clinical trials for wet AMD and DME. The company has strong financial backing and a potential first-in-class gene therapy drug, 4D-150, with a favorable safety profile and potential for significant treatment burden reduction. However, risks to the company's investment thesis include failure to secure capital resources and potential limitations in achieving peak commercial revenue estimates.
Bears say
4D Molecular Therapeutics is facing several risks that may impact its ability to achieve its target price. These risks include the potential for clinical setbacks, as well as manufacturing and regulatory challenges. While the company has demonstrated delivery in various target tissues, the novelty and complexity of gene therapy products could lead to delays and unforeseen safety issues. Furthermore, while the company's pipeline is focused on larger indications with potential for commercial success, there is no guarantee that it will receive significant market share. As a result, our financial analysis suggests a negative outlook for 4D Molecular Therapeutics' stock.
This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
FDMT Analyst Forecast & Price Prediction
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares